Autologous NK Cell Therapy for Solid Tumors: Lecheng’s Adjunctive Option
Kayleen Gromoll2026-08-01T16:32:47+08:00Autologous NK cell therapy for solid tumors in Lecheng: efficacy, limitations, costs, and patient selection.
Approved Stem Cell Therapy for Type 2 Diabetes at Lecheng Ciming
James W. Watson2026-08-01T16:00:51+08:00Discover the approved MSC therapy for refractory type 2 diabetes at Lecheng Ciming. Evidence-based outcomes, weight-based pricing, and a complete patient guide.
New Stem Cell Hope for Cirrhosis at Lecheng Maisel
Kayleen Gromoll2026-08-01T16:33:00+08:00Discover VUM02 stem cell therapy for decompensated cirrhosis at Lecheng Maisel. Evidence‑based, off‑the‑shelf, and now available. Learn costs, mechanisms, and who qualifies.
BNCT at Lecheng: Precision Radiotherapy and New Frontiers in Cancer Care
Lecheng2026-07-14T13:18:22+08:00Within the rapidly evolving landscape of oncology at the Lecheng International Medical Tourism Pilot Zone, I have witnessed the convergence of global innovation and clinical need. Among the most compelling advances is the arrival of Boron Neutron Capture Therapy (BNCT), a modality that compels us to reconsider the fundamental paradigms of radiation oncology. It moves beyond [...]
Airway Basal Stem Cells for COPD: Lecheng’s Regenerative Option
James W. Watson2026-08-01T16:32:39+08:00Explore airway basal stem cell therapy for COPD at Ruijin Lecheng. Review clinical evidence, patient criteria, cost, and mechanisms of this regenerative lung treatment.
AngioExpert Debut in China: Non-Invasive Heart Risk Test at Lecheng
James W. Watson2026-07-25T15:23:18+08:00Experience the China debut of AngioExpert at Boao Lecheng – a painless, needle-free cardiovascular risk assessment tool that reveals hidden microvascular issues for early prevention.
Zero-Tariff Y-90 Microspheres: A New Liver Cancer Hope at Lecheng
Kayleen Gromoll2026-07-25T14:06:15+08:00Discover how Hainan’s zero-tariff policy makes Y-90 glass microsphere therapy more affordable for liver cancer patients. Learn about breakthrough procedures at Lecheng bringing renewed hope.
Lecheng Introduces Veregen: A New Botanical Treatment for HPV Warts
Kayleen Gromoll2026-07-22T13:45:32+08:00Lecheng introduces Veregen, a groundbreaking botanical drug for treating HPV genital warts. Discover this non-invasive treatment offering lower recurrence and less pain.
Axhidrox: Europe’s First Hyperhidrosis Cream at Lecheng
James W. Watson2026-07-10T13:03:14+08:00Axhidrox, the first topical glycopyrronium cream for severe axillary hyperhidrosis, cuts sweating by 82% with minimal side effects. Approved in Europe, the US, and now available in China via Lecheng's pilot zone. Discover the non-invasive solution today.
Dexycu: China’s First Single-Injection Cataract Drug via Lecheng RWD
James W. Watson2026-07-02T11:35:43+08:00Discover Dexycu, the first single‑injection sustained‑release steroid for post‑cataract inflammation, now approved in China via Lecheng's real‑world data pathway. No more eye drops – one injection heals for 3 weeks.
